Drugs / RB042
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07285122 | Feb 2026 → Feb 2027 expected | — | Atisama Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RB042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07285122 ↗ |
| Route | Inhaled | “administered via a nebuliser” NCT07285122 ↗ |